Mitral Valve Prolapse (MVP) if one of the most frequent cardiovascular disease, and is associated with an important burden in term of morbidity and mortality. There is currently no pharmacological therapy for the patients suffering from MVP, the only available option is to perform an open heart surgery to replace or repair the diseased valve.
Based on the genetic findings, we have developped an unique model to study this disease. Our project aims to decipher the mechanisms leading to MVP, in order to identify potential therapeutic target for this disease.